glucagon receptor antagonists3

AMPA receptor antagonist-3 is an AMPA receptor antagonist.

Calcium-Sensing Receptor Antagonists I functions as an antagonist to the parathyroid hormone receptors that sense calcium.

Sigma-1 receptor antagonist 3 is a potent and selective antagonist of Sigma-1 (σ1) receptor(Ki : 1.14 nM), has the potential for the neuropathic pain.

Compound 5e, a GPR34 receptor antagonist, exhibits selective inhibition of lysophosphatidylserine-induced ERK1/2 phosphorylation in a dose-dependent manner, demonstrating an IC50 value of 0.680 μM without significant cytotoxicity. Additionally, it displays antisensory activity in a mouse neuropathic pain model [1].

RXFP1 receptor agonist-3 (Example 223) is an agonist of the RXFP1 receptor that inhibits cyclic AMP (cAMP) production in HEK293 cells stably expressing human RXFP1, boasting an EC50 of 2 nM [1].

EP4 receptor antagonist 3 is a highly potent and specific inhibitor of the EP4 receptor. It is intended for research purposes in studying EP4 receptor-mediated diseases such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, and cancer.

Glucagon receptor antagonist -3 is a highly effective glucagon receptor antagonist.

Mu opioid receptor antagonist 3 (compound 26) is a potent and selective mu opioid receptor (MOR) antagonist that penetrates the blood-brain barrier (Ki: 0.24 nM, EC50: 0.54 nM). Mu opioid receptor antagonist 2 can be used to study opioid use disorder (OUD).

Adenosine receptor antagonist 3 has the potential for cancer disease research which is a potent adenosine receptor antagonist [1].

TGR5 Receptor Agonist 3 is a G protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonist soft drug compound that decreases gallbladder filling, exhibits good gallbladder safety, and is able to act on hTGR5 (EC50: 16.4 nM) and mTGR5 (EC50: 209 nM).

Androgen receptor antagonist 3 (Compound C18) has anticancer activities that is an antagonist of androgen receptor (AR) (IC 50 = 2.4 μM) [1].

NMDA receptor modulator 3 (Compound 99) is a potent modulator of NMDA receptor that can be used in the research of neurological disorder [1].

Glucagon receptor antagonist -1 is a highly effective glucagon receptor antagonist.

GLP-1 receptor agonist 3 is a GLP-1 receptor agonist,Example 4A-1, has EC50s of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell lines assay, respectively.

Estrogen receptor antagonist 3 is a potent degradation agent of the estrogen receptor (ER). Estrogen signalling systems play an important role in the regulation of cell growth, differentiation and apoptosis, and Estrogen receptor antagonist 4 has shown potential for research into cancer diseases.

Androgen Receptor Degrader-3 (ARD-3) is a compound that inhibits androgen receptor signaling and promotes the degradation of the receptor, with potential applications in prostate cancer research [1].

Orexin receptor antagonist 3 (example 216) is an orexin receptor antagonist.

A2A receptor antagonist 3 (Example 92) is an adenosine A2a receptor antagonist (Ki: 0.4 nM). receptor (Ki: 1467 nM).

Protease-Activated Receptor-1 antagonist 3 is a potent antagonist (IC50: 7 nM) of Protease-Activated Receptor 1protease-activated receptor-1. antagonist 3 exhibits binding affinity to hERG K+ channels (IC50: 9 μM).

Glucagon receptor antagonist I is a competitive antagonist of the glucagon receptor (GCGR; IC50 = 181 nM). It blocks glucagon-induced glycogenolysis in primary human hepatocytes and isolated liver. Glucagon receptor antagonist I, at 50 mg/kg, reduces the increase in glucose levels observed after intraperitoneal administration of glucagon in humanized mice. Glucagon receptor antagonist inactive control does not prevent glucagon-mediated actions.

GP 2A is a selective agonist of CB2 receptor.

NMDA receptor antagonist-3 is a NMDA receptor antagonist with a significan recovery rate (40.0%, at 100 μM) and safe toxicological characteristics in SH-SY5Y and human adipose mesenchymal stem cells.

ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating monocrotaline-induced PAH in a rat model [1].

TFRGAP-amide, human PAR-3-derived tethered ligand sequence which does not activate PAR-3 but rather activates PAR-1 and PAR-2, either in Jurkat or in other PAR-expressing cells.

P2X7 receptor antagonist-3 is a powerful inhibitor of the P2X7 receptor, exhibiting IC50 values of 4.2 nM in humans and 6.8 nM in rats, indicating its high potency in both species.

Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a peptide that acts as an agonist for the proteinase-activated receptor (PAR-3)[1].

Glucagon receptor antagonist -2 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonists-5 is an orally bioavailable indazole-based glucagon receptor antagonist (Ki: 32 nM). It has potential for the treatment of type 2 diabetes mellitus (T2DM).

5-HT2A receptor agonist-3 represents the highest selectivity for the human 5-HT2A receptor currently identified, exhibiting a K i of 2.5 nM. It also demonstrates a remarkable 124-fold selectivity over its structurally analogous 5-HT2C receptor [1].

Compound 20, identified as μ opioid receptor agonist 3, is a potent µOR agonist that exhibits an EC50 value of 0.87 nM. It holds promise for research into pain management and neuropsychiatric disorders [1].

APJ receptor agonist 3 is a highly effective and orally administerable agonist of the APJ receptor, demonstrating a potent EC50 value of 0.027 nM.

Glucagon Receptor Antagonist Inactive Control is a Glucagon receptor antagonist that can be used in related research in the field of life sciences. Its product number is T36580 and CAS number is 362482-00-6.